Batsheva Kerem

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/345534/publications.pdf

Version: 2024-02-01

46 papers	4,894 citations	186265 28 h-index	223800 46 g-index
50 all docs	50 docs citations	50 times ranked	5814 citing authors

#	Article	IF	Citations
1	Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation. Journal of Cystic Fibrosis, 2022, 21, 630-636.	0.7	18
2	Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10Âkb C-to-T splicing mutation. Journal of Cystic Fibrosis, 2021, 20, 865-875.	0.7	30
3	3D genome organization contributes to genome instability at fragile sites. Nature Communications, 2020, 11, 3613.	12.8	46
4	New approaches to genetic therapies for cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, S54-S59.	0.7	46
5	AT-dinucleotide rich sequences drive fragile site formation. Nucleic Acids Research, 2019, 47, 9685-9695.	14.5	28
6	Take it personally: how personal we reach when we are so different from each other?. Journal of Cystic Fibrosis, 2019, 18, 6-7.	0.7	3
7	Genomic instability in fragile sitesâ€"still adding the pieces. Genes Chromosomes and Cancer, 2019, 58, 295-304.	2.8	15
8	DNA replication stress drives fragile site instability. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2018, 808, 56-61.	1.0	19
9	The suppression of premature termination codons and the repair of splicing mutations in CFTR. Current Opinion in Pharmacology, 2017, 34, 125-131.	3.5	30
10	Oncogene-Induced Replication Stress Drives Genome Instability and Tumorigenesis. International Journal of Molecular Sciences, 2017, 18, 1339.	4.1	18
11	The complex nature of fragile site plasticity and its importance in cancer. Current Opinion in Cell Biology, 2016, 40, 131-136.	5.4	56
12	Continuous chromosomal instability in human pluripotent stem cells â€“ the role of DNA replication. Molecular and Cellular Oncology, 2016, 3, e1183743.	0.7	3
13	Identification of Dormancy-Associated MicroRNAs for the Design of Osteosarcoma-Targeted Dendritic Polyglycerol Nanopolyplexes. ACS Nano, 2016, 10, 2028-2045.	14.6	64
14	Genomic Instability in Human Pluripotent Stem Cells Arises from Replicative Stress and Chromosome Condensation Defects. Cell Stem Cell, 2016, 18, 253-261.	11.1	106
15	The presence of extra chromosomes leads to genomic instability. Nature Communications, 2016, 7, 10754.	12.8	235
16	To break or not to break â€“ context matters. Molecular and Cellular Oncology, 2016, 3, e1072657.	0.7	1
17	Folate levels modulate oncogeneâ€induced replication stress and tumorigenicity. EMBO Molecular Medicine, 2015, 7, 1138-1152.	6.9	28
18	Oncogenes create a unique landscape of fragile sites. Nature Communications, 2015, 6, 7094.	12.8	72

#	Article	IF	Citations
19	The unfolded protein response affects readthrough of premature termination codons. EMBO Molecular Medicine, 2014, 6, 685-701.	6.9	31
20	Interplay between genetic and epigenetic factors governs common fragile site instability in cancer. Cellular and Molecular Life Sciences, 2014, 71, 4495-4506.	5.4	26
21	Transcriptional Dynamics in Colorectal Carcinogenesis: New Insights into the Role of c-Myc and miR17 in Benign to Cancer Transformation. Cancer Research, 2014, 74, 5532-5540.	0.9	19
22	The complex basis underlying common fragile site instability in cancer. Trends in Genetics, 2012, 28, 295-302.	6.7	72
23	Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development. Cell, 2011, 145, 435-446.	28.9	685
24	Failure of Origin Activation in Response to Fork Stalling Leads to Chromosomal Instability at Fragile Sites. Molecular Cell, 2011, 43, 122-131.	9.7	157
25	Impaired Replication Stress Response in Cells from Immunodeficiency Patients Carrying Cernunnos/XLF Mutations. PLoS ONE, 2009, 4, e4516.	2.5	19
26	Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet, The, 2008, 372, 719-727.	13.7	364
27	FRA18C: a new aphidicolin-inducible fragile site on chromosome 18q22, possibly associated with in vivo chromosome breakage. Journal of Medical Genetics, 2007, 44, 347-352.	3.2	24
28	Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. Journal of Clinical Investigation, 2007, 117, 683-692.	8.2	252
29	The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells. European Journal of Human Genetics, 2007, 15, 1156-1162.	2.8	102
30	The molecular basis of common and rare fragile sites. Cancer Letters, 2006, 232, 13-26.	7.2	131
31	The splicing machinery is a genetic modifier of disease severity. Trends in Genetics, 2005, 21, 480-483.	6.7	72
32	Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. Genes and Development, 2005, 19, 2715-2726.	5.9	114
33	Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation. EMBO Reports, 2004, 5, 1071-1077.	4.5	65
34	Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis andCFTRStop Mutations. New England Journal of Medicine, 2003, 349, 1433-1441.	27.0	473
35	Molecular Basis for Expression of Common and Rare Fragile Sites. Molecular and Cellular Biology, 2003, 23, 7143-7151.	2.3	211
36	A role for common fragile site induction in amplification of human oncogenes. Cancer Cell, 2002, 1, 89-97.	16.8	267

#	Article	IF	Citations
37	Splicing regulation as a potential genetic modifier. Trends in Genetics, 2002, 18, 123-127.	6.7	197
38	A Pilot Study of the Effect of Gentamicin on Nasal Potential Difference Measurements in Cystic Fibrosis Patients Carrying Stop Mutations. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 860-865.	5.6	202
39	Replication Delay along FRA7H, a Common Fragile Site on Human Chromosome 7, Leads to Chromosomal Instability. Molecular and Cellular Biology, 2000, 20, 4420-4427.	2.3	110
40	Clinical and Genetic Risk Factors for Cystic Fibrosis-related Liver Disease. Pediatrics, 1999, 103, 52-57.	2.1	108
41	Screening of CFTR mutations in an isolated population: identification of carriers and patients. European Journal of Human Genetics, 1998, 6, 181-184.	2.8	11
42	The Molecular Basis of Disease Variability among Cystic Fibrosis Patients Carrying the 3849+10 kb Câ†'T Mutation. Genomics, 1998, 53, 276-283.	2.9	87
43	Genotype-phenotype correlations in cystic fibrosis. , 1996, 22, 387-395.		102
44	Genotypeâ€phenotype correlations in cystic fibrosis. Pediatric Pulmonology, 1996, 22, 387-395.	2.0	4
45	The Molecular Basis for Disease Variability in Cystic Fibrosis. European Journal of Human Genetics, 1996, 4, 65-73.	2.8	101
46	Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel. Human Genetics, 1995, 96, 193-197.	3.8	63